Barclays analyst Saket Kalia maintained a Hold rating on Definitive Healthcare Corp (DH – Research Report) on August 5 and set a price target of $23.00. The company’s shares closed last Friday at $24.51.
According to TipRanks, Kalia is a 5-star analyst with an average return of 14.4% and a 56.52% success rate. Kalia covers the Technology sector, focusing on stocks such as Adobe, Autodesk, and Fortinet.
Currently, the analyst consensus on Definitive Healthcare Corp is a Moderate Buy with an average price target of $28.20.
See the top stocks recommended by analysts >>
The company has a one-year high of $50.30 and a one-year low of $14.76. Currently, Definitive Healthcare Corp has an average volume of 596.7K.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Definitive Healthcare Corp is a leading provider of healthcare commercial intelligence. The company’s solutions provide accurate and comprehensive information on healthcare providers and their activities to help our customers optimize everything from product development to go-to-market planning and sales and marketing execution.
Read More on DH:
